Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of rosiglitazone on renal hemodynamics and proteinuria in type 2 diabetic nephropathy
2005-002407-17Phase 4Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rosiglitazone in diabetic glomerulosclerosis, chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Technische Universität Dresden. Primary endpoint: 24-hour urinary protein excretion at 52 weeks. Started Dec 2005; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-002407-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002407-17.